Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
Completed
- Conditions
- Urinary Incontinence
- Interventions
- Biological: botulinum toxin Type A
- Registration Number
- NCT02072928
- Lead Sponsor
- Allergan
- Brief Summary
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are prescribed BOTOX® as standard of care in clinical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
- Patients prescribed BOTOX® for urine incontinence from NDO due to spinal injury or MS as standard of care in clinical practice in Belgium
- Previous treatment with anticholinergic drugs ineffective
- Last BOTOX® treatment ≥18 months.
Exclusion Criteria
- Diagnosis of urinary incontinence less than 9 months.
- No anticholinergic drug use in the last 9 months.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description BOTOX® botulinum toxin Type A Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
- Primary Outcome Measures
Name Time Method Change From Baseline in Anticholinergic Drug Use Baseline, 9 Months Anticholinergic drug use was collected the 9 months before the baseline Botox® treatment and the 9 months following the baseline Botox® treatment. Total anticholinergic drug use in the 9 months following the baseline Botox® treatment is noted.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
CHU de Liège
🇧🇪Esneux, Belgium
UZA
🇧🇪Edegem, Belgium
Maria Ziekenhuis Noord-Limburg
🇧🇪Overpelt, Belgium
Centre Hospitalier Regional de Huy
🇧🇪HUY, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
UZ Gent
🇧🇪Ghent, Belgium